OverviewSuggest Edit

CureVac is a biotechnology company that is active in the field of messenger RNA (mRNA) technology. Using mRNA it is able to directly give the body the information it needs to fight disease. CureVac mainly focuses on three therapeutic areas: cancer immunotherapies, prophylactic vaccines, and protein delivery.

TypePrivate
Founded2000
HQTübingen, DE
Websitecurevac.com

Latest Updates

Employees (est.) (May 2020)400(+4%)
Job Openings101
Revenue (FY, 2018)€12.6 M(+93%)
Cybersecurity ratingAMore

Key People/Management at CureVac

Ingmar Hoerr

Ingmar Hoerr

Founder
Franz-Werner Haas

Franz-Werner Haas

CEO
Florian von der Mulbe

Florian von der Mulbe

Chief Production Officer & Co-Founder
Pierre Kemula

Pierre Kemula

Chief Financial Officer
Mariola Fotin-Mleczek

Mariola Fotin-Mleczek

CTO
Igor Splawski

Igor Splawski

CSO
Show more

CureVac Office Locations

CureVac has offices in Tübingen, Frankfurt am Main and Boston
Tübingen, DE (HQ)
Friedrich-Miescher-Straße 15
Frankfurt am Main, DE
Schumannstr. 27
Tübingen, DE
Paul-Ehrlich-Straße 15
Boston, MA, US
250 Summer St 3rd Fl
Show all (4)

CureVac Financials and Metrics

Summary Metrics

Founding Date

2000

CureVac total Funding

$1.1 b

CureVac latest funding size

$640 m

Time since last funding

a year ago

CureVac investors

CureVac's latest funding round in July 2020 was reported to be $640 m. In total, CureVac has raised $1.1 b. CureVac's latest valuation is reported to be $1.5 b.
View all funding rounds

CureVac Revenue

Embed Graph
View revenue for all periods
CureVac's revenue was reported to be €12.55 m in FY, 2018 which is a 92.1% increase from the previous period.
EUR

Revenue (FY, 2018)

12.6m

Revenue growth (FY, 2017 - FY, 2018), %

92.1%

Gross profit (FY, 2018)

(9.8m)

Gross profit margin (FY, 2018), %

(78%)

Net income (FY, 2018)

(74.6m)

Market valuation

1.5b

Cash (31-Dec-2018)

60.9m

EV

1.4b
EURFY, 2016FY, 2017FY, 2018

Revenue

10.8m6.5m12.6m

Revenue growth, %

(39%)92%

Cost of goods sold

11.1m17.1m22.3m

Gross profit

(373.4k)(10.6m)(9.8m)
EURFY, 2016FY, 2017FY, 2018

Cash

134.2m146.0m60.9m

Accounts Receivable

4.2m760.0k5.6m

Prepaid Expenses

778.0k446.9k5.9m

Inventories

5.4m3.7m4.1m
EURFY, 2017FY, 2018

Depreciation and Amortization

3.1m3.6m

Accounts Payable

42.3m3.2m

Cash From Operating Activities

(14.0m)(73.7m)

Purchases of PP&E

(19.1m)(9.4m)
EURFY, 2016

Revenue/Employee

85.3k

Debt/Equity

0.1 x

Financial Leverage

1.4 x
Show all financial metrics

CureVac Operating Metrics

Mar, 2020May, 2020

Patent Applications

500

Patents Issued

700233

Phase I Trials Products

33

Technology Partners

22
Show all operating metrics

CureVac Acquisitions / Subsidiaries

Company NameDateDeal Size
CureVac Inc.
CureVac Real Estate GmbH

CureVac Revenue Breakdown

Embed Graph

CureVac revenue breakdown by business segment: 37.3% from Goods Deliveries and 62.7% from Services

CureVac revenue breakdown by geographic segment: 78.3% from Foreign and 21.7% from Germany

CureVac Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

CureVac Online and Social Media Presence

Embed Graph

CureVac News and Updates

CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primates

Shares of CureVac N.V. gained 0.4% in morning trading Monday, but bucked the selloff in the biotechnology sector and the broader stock market, after the Germany-based company revealed upbeat preclinical data regarding its vaccine candidates against the coronavirus that causes COVID-19, in non-human…

Thinking about trading options or stock in CureVac, Coinbase, Advanced Micro Devices, Moderna, or AMC Entertainment?

NEW YORK, Aug. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CVAC, COIN, AMD, MRNA, and AMC. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

CureVac to 'plow forward' with Covid vaccine despite disappointing results

CureVac plans to continue work on its Covid-19 vaccine despite disappointing clinical trial results that showed the shot is just 48% effective.

The Wall Street Journal: CureVac says COVID-19 vaccine was 48% effective in key study

German company CureVac released the final results for its once-promising Covid-19 vaccine, finding it provided less protection than the vaccines already authorized for use in the U.S.

CureVac Drops After Full Data Show Covid Vaccine Trails Rivals

CureVac Drops After Full Data Show Covid Vaccine Trails Rivals
Show more

CureVac Blogs

[English only] CureVac Announces Voting Results of General Meeting

The post [English only] CureVac Announces Voting Results of General Meeting appeared first on CureVac.

[English only] Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV

The post [English only] Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV appeared first on CureVac.

CureVac Frequently Asked Questions

  • When was CureVac founded?

    CureVac was founded in 2000.

  • Who are CureVac key executives?

    CureVac's key executives are Ingmar Hoerr, Franz-Werner Haas and Florian von der Mulbe.

  • How many employees does CureVac have?

    CureVac has 400 employees.

  • What is CureVac revenue?

    Latest CureVac annual revenue is €12.6 m.

  • What is CureVac revenue per employee?

    Latest CureVac revenue per employee is €31.4 k.

  • Who are CureVac competitors?

    Competitors of CureVac include Stemirna, RNACure and RNAimmune.

  • Where is CureVac headquarters?

    CureVac headquarters is located at Friedrich-Miescher-Straße 15, Tübingen.

  • Where are CureVac offices?

    CureVac has offices in Tübingen, Frankfurt am Main and Boston.

  • How many offices does CureVac have?

    CureVac has 4 offices.